Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW Mulls Sakigake System for SaMD with Medical Device as a Model: Official
June 3, 2021
- LDP Group on Generics Calls for Sustainable Supply Scheme: Proposal
June 3, 2021
- Japan to Establish Ecosystem to Deliver Innovative Drugs: Draft Growth Strategy
June 3, 2021
- Deregulation Panel Prods Govt to Fuel SaMD Development
June 3, 2021
- Govt to Build R&D Data Utilization Platform at AMED
June 3, 2021
- Nonpartisan Lawmakers’ Group Launched for Dementia Measures
June 2, 2021
- Japan Cabinet Hammers Out Strategy to Boost Vaccine Development
June 2, 2021
- Japan to Roll Out COVID-19 Vaccines at Workplaces from June 21
June 2, 2021
- Blue Letter Issued to OA Drug Joyclu after Anaphylaxis Reports
June 2, 2021
- Manufacturing and Use of Cannabis-Derived Drugs Should Be Permitted: MHLW Panel
June 2, 2021
- Eisai’s EZH2 Inhibitor, 3 More New Drugs Clear Key Panel, June OK Likely
May 31, 2021
- Panel OK’s Pfizer Vaccine Use in Age 12-Plus, Longer Refrigerator Storage
May 31, 2021
- Olumiant Added to MHLW’s COVID-19 Guide as Approved Drug
May 28, 2021
- LDP Lawmakers Urge Expanded Fertility Treatment Support via Coverage, Subsidies
May 28, 2021
- Japan Approves Rinvoq for Psoriasis, More Drugs for Label Expansions
May 28, 2021
- MHLW Panels to Analyze Group-Based Data for Post-COVID-19 Vaccination Deaths
May 27, 2021
- Japan Panel Clears 1st Oral SMA Drug, 2 Migraine Meds, RNAi Therapy and More
May 27, 2021
- Next Drug Distribution Confab Set for July 2 after Bid-Rigging Verdicts
May 27, 2021
- Trintellix Braced for Price Cut as Chuikyo OKs CEA Results, Coralan Intact
May 27, 2021
- Chuikyo to Discuss Evaluation Rule for SaMD toward Next Reimbursement Reform
May 27, 2021
ページ
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…